UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

November 4, 2021

INNOVATE CORP.

<u>Delaware</u> (State or other jurisdiction of incorporation)	<u>001-35210</u> (Commission File Number)	<u>54-1708481</u> (I.R.S. Employer Identification No.)
295 Madison Avenue, 12th Floor New York, NY		10017
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code:		(212) 235-2690

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered						
Common Stock, par value \$0.001 per share	VATE	New York Stock Exchange						

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition

On November 4, 2021, INNOVATE Corp. (F/K/A HC2 Holdings, Inc.) (the "Company") issued a press release setting forth its results for the three and nine months ended September 30, 2021 (the "Earnings Release") and posted the HC2 Holdings, Inc. Third Quarter 2021 Conference Call investor presentation to its Investor Relations section of the Company's website at http://www.innovatecorp.com.

A copy of the Earnings Release and the investor presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure

As previously announced, the Company will conduct a conference call today, Thursday, November 4, 2021 at 4:30 p.m. The presentation slides to be used during the call, attached hereto as Exhibit 99.2, will be available on the "Investor Relations" section of the Company's website (<u>http://www.innovatecorp.com</u>) immediately prior to the call. The conference call and the presentation slides will be simultaneously webcast on the "Investor Relations" section of the Company's website beginning at 4:30 p.m. ET on Thursday, November 4, 2021. The information contained in, or that can be accessed through the Company's website is not a part of this filing.

The information set forth in (and incorporated by reference into) this Item 7.01, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.2, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

d. Exhibits	
Exhibit	
No.	Description
99.1	Press Release of INNOVATE Corp., dated November 4, 2021
99.2	INNOVATE Corp. Third Quarter 2021 Conference Call Investor Presentation
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INNOVATE Corp.

November 4, 2021

By: /s/ Michael J. Sena

Name: Michael J. Sena Title: Chief Financial Officer

NOT FOR IMMEDIATE RELEASE

INNOVATE Corp. Announces Third Quarter 2021 Results

- Infrastructure: DBM Global maintains backlog of \$1.6 billion while converting \$383.0 million of revenue in Q3 -

- Life Sciences: Glacial Rx^\circledast receives milestone FDA approval -

- Spectrum: Broadcasting delivers fourth consecutive quarter of profitability -

New York, November 4, 2021 - INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE: VATE) announced today its consolidated results for the third quarter ended September 30, 2021.

Financial Summary	
-------------------	--

(in millions, except per share amounts)	Three Months Ended September 30,						Nine Months Ended September 30,					
		2021		2020	Increase / (Decrease)	_	2021	2020		Increase / (Decrease)		
Revenue	\$	394.8	\$	170.5	131.6 %	\$	810.4	\$	538.9	50.4 %		
Net loss attributable to common stock and participating preferred stockholders	\$	(213.0)	\$	(17.7)	(1103.4)%	\$	(224.5)	\$	(88.5)	(153.7)%		
Diluted loss per share - Net loss attributable to common stock and participating preferred shareholders	\$	(2.75)	\$	(0.37)	(643.2)%	\$	(2.92)	\$	(1.89)	(54.5)%		
Total Adjusted EBITDA	\$	14.3	\$	7.8	83.3 %	\$	21.8	\$	15.5	40.6 %		

Reconciliation of GAAP to Non-GAAP measures follows
 Note that Total Adjusted EBITDA excludes results for discontinued operations

Commentary

"INNOVATE's strong third quarter results highlight the successful refocusing of our business to three key areas of the new economy - Infrastructure, Life Sciences and Spectrum," said Avie Glazer, Chairman of INNOVATE. "All three of our operating segments performed well during the quarter, with our Infrastructure segment having more than doubled revenue while maintaining a backlog of \$1.6 billion, underscoring its substantial growth and cash generation potential; Life Sciences having received an important milestone FDA approval and Spectrum having delivered its fourth consecutive quarter of profitability. As INNOVATE's strategic transformation continues, we are excited about our future."

"We are laser-focused on executing against our strategic plan on a platform that was purpose-built to grow with the new economy and within dynamic industries," said Wayne Barr, Jr., Chief Executive Officer of INNOVATE. "The strong leadership in place at each of the business segments helped drive top line growth in the third quarter. With one full quarter of the Banker Steel acquisition under our belt, our Infrastructure segment had significant revenue growth, expanded its geographic footprint, and maintained robust backlog levels. At Life Sciences, R2's Glacial Rx[®] continues to make headway, earning its third FDA indication and unique product

code in September. At Spectrum, we delivered Adjusted EBITDA of \$1.8 million versus an Adjusted EBITDA loss of \$0.2 million in the prior year period, driven in part by our significant efforts to optimize operations, along with growth in our Station Group OTA revenues."

Third Quarter 2021 Highlights

- INNOVATE completed its successful name change, launched its rebranding efforts and began trading under its new ticker symbol, "VATE." The completion of the name change reflects the Company's focus on innovative growth businesses, including its best-in-class Infrastructure, Life Sciences and Spectrum segments.
- The Company also completed the sale of its Insurance segment to Continental General Holdings LLC, an affiliate of Michael Gorzynski, a director of the Company and beneficial owner of approximately 6.6% of the Company's outstanding stock, for a transaction valued at approximately \$90 million. At closing, INNOVATE received \$65 million in cash, and Continental General Insurance Company transferred to INNOVATE approximately \$25 million of securities, comprised of certain Broadcasting segment securities held directly by the Insurance segment.

Infrastructure

- DBM Global performed well in the quarter and continues to see improving demand in the commercial and industrial construction markets. Additionally, DBM Global is poised to benefit from the proposed bipartisan infrastructure bill, which is expected to generate increased demand for large and complex projects starting as early as 12 to 18 months from a signed bill.
- For the third quarter of 2021, DBM Global reported revenue of \$383.0 million, an increase of 138.2% compared to \$160.8 million in the prior year quarter. Net Income was \$6.9 million, compared to \$2.4 million for the prior year quarter. Adjusted EBITDA increased to \$24.4 million from \$17.7 million in the prior year quarter.
- DBM Global's total backlog increased to \$1,605.9 million as of September 30, 2021, up from \$394.5 million as of December 31, 2020. Taking into consideration awarded, but not yet signed contracts, backlog would have been approximately \$1,889 million at the end of the third quarter of 2021, compared to \$608 million at the end of the fourth quarter of 2020.

Life Sciences

- INNOVATE provided an additional \$15 million to R2 to increase its ownership stake in R2 and accelerate the sales effort as the launch of commercial shipments to U.S. aesthetic providers for Glacial Rx[®] continues as planned.
- Glacial Rx[®] earned a third FDA indication and unique product code as it became the first and only Class II dermal cooling system FDA-cleared for general dermabrasion, scar and acne scar revision, and tattoo removal, permanently changing the aesthetics industry. This is a major milestone for this product as Glacial Rx[®] is now in its own FDA-issued product code instead of being lumped into one classification, among hundreds of devices.

<u>Spectrum</u>

- Broadcasting is focused on generating growth in commercial carriage through both lease and revenue share arrangements with digital content providers, while continuing to improve its operations. Broadcasting also plans to add 24 new stations using existing construction permits by the end of the first quarter 2022 to its already industry-leading 227 broadcast stations.
- · Broadcasting reached an agreement with Cisneros Media to launch Novelisima in September, a new Spanish language network that broadcasts telenovelas in more than 70 markets in the US on Broadcasting's platform.
- Increased the distribution of the beIN EXTRA Sports networks offering the most comprehensive free ad-supported live sports programming "over the air".
- For the third quarter of 2021, Broadcasting reported revenue of \$10.2 million, an increase of 5.2% compared to 9.7 million in the prior year quarter. The increase was primarily driven by higher station revenues as the Spectrum segment launched new

customers and grew the number of its operating stations. This was partially offset by a decrease in revenue from the sale of full power stations.

- For the third quarter of 2021, Broadcasting reported Net Loss of \$4.1 million compared to \$14.6 million in the prior year quarter. Adjusted EBITDA was a positive \$1.8 million, compared to an Adjusted EBITDA loss of \$0.2 million in the prior year quarter. Broadcasting's results for the quarter reflect the significant efforts to improve operations and reduce costs across the platform, the sale of high-cost non-core stations and the growth in revenues described above, which led to the fourth consecutive quarter of positive Adjusted EBITDA.
- As of September 30, 2021, Broadcasting operates 223 stations, of which 218 are currently connected to its CentralCast system. The total Broadcasting footprint includes operating stations in 94 markets in the U.S. and Puerto Rico, including operating stations in 34 of the top 35 DMAs.

Third Quarter Financial Highlights

•

Revenue: For the third quarter of 2021, INNOVATE consolidated revenue from continuing operations was \$394.8 million, an increase of 131.6% compared to \$170.5 million for the prior year quarter. The increase in revenue was due primarily to the Company's Infrastructure segment, driven by the contribution from Banker Steel, which was acquired in the second quarter of 2021, as well as from higher revenues across DBM Global's service offerings attributable to timing of project work under execution and backlog mix.
 REVENUE by OPERATING SEGMENT

REVENUE by OPERATING SEGME	NI												
(in millions)			Three Months	Ended September	30,		Nine Months Ended September 30,						
		2021		2020		Increase / (Decrease)		2021		2020		Increase / (Decrease)	
Infrastructure	\$	383.0	\$	160.8	\$	222.2	\$	776.3	\$	509.6	\$	266.7	
Life Sciences		1.6		_		1.6		2.8		_		2.8	
Spectrum		10.2		9.7		0.5		31.3		29.3		2.0	
Consolidated INNOVATE	\$	394.8	\$	170.5	S	224.3	\$	810.4	\$	538.9	\$	271.5	

Net Income (Loss): For the third quarter of 2021, INNOVATE reported a Net Loss attributable to common stock and participating preferred stockholders of \$213.0 million, or \$2.75 per fully diluted share, compared to a Net Loss of \$17.7 million, or \$0.37 per fully diluted share, for the prior year quarter. The decrease was driven by a change in Income (Loss) from Discontinued Operations as a result of the sale of the Insurance business in the third quarter 2021. The decrease was partially offset from the Spectrum segment as a result of significant efforts to improve operations and reduce costs across the platform, the sale of high-cost non-core stations in the second half of 2020, a reduction in asset impairments in the current period and growth in Station Group OTA revenues, as well as from the Infrastructure segment, driven by the contribution from Banker Steel, which was acquired in the second quarter of 2021.

NET INCOME (LOSS) by OPERATING SEGMENT

(in millions)	-		Three Months	Ended Septemb	er 30,		Nine Months Ended September 30,						
		2021		2020	Increas	se / (Decrease)	2021		2020		Increas	e / (Decrease)	
Infrastructure	\$	6.9	\$	2.4	\$	4.5	\$	8.3	\$	4.0	\$	4.3	
Life Sciences		(5.1)		(4.3)		(0.8)		(13.6)		(8.7)		(4.9)	
Spectrum		(4.1)		(14.6)		10.5		(9.6)		(23.8)		14.2	
Non-operating Corporate		(8.0)		(8.0)		_		(58.0)		(72.0)		14.0	
Other and Eliminations		(1.3)		(1.0)		(0.3)		—		68.6		(68.6)	
Net (loss) income attributable to INNOVATE Corp., excluding discontinued operations	\$	(11.6)	\$	(25.5)	\$	13.9	\$	(72.9)	\$	(31.9)	\$	(41.0)	
Net (loss) income from discontinued operations		(200.3)		8.2		(208.5)		(149.9)		(55.4)		(94.5)	
Net loss attributable to INNOVATE Corp.	\$	(211.9)	\$	(17.3)		(194.6)		(222.8)		(87.3)		(135.5)	
Less: Preferred dividends and deemed dividends from conversions		1.1		0.4		0.7		1.7		1.2		0.5	
Net loss attributable to common stock and participating preferred stockholders	\$	(213.0)	\$	(17.7)	\$	(195.3)	\$	(224.5)	\$	(88.5)	\$	(136.0)	

• Adjusted EBITDA: For the third quarter of 2021, Total Adjusted EBITDA, which excludes discontinued operations, was \$14.3 million, compared to Total Adjusted EBITDA of \$7.8 million for the prior year quarter. The increase in Adjusted EBITDA can be attributed to the contribution from Banker Steel at the Infrastructure segment, which was acquired in the second quarter of 2021, as well as from the Spectrum segment as a result of Azteca cost reductions, a decrease in compensation, rent, consulting and overhead expenses, as well as higher station revenues as Station Group grew the number of operating stations and launched new customers across its broadcast platform. The increase was partially offset from timing of project work under execution, changes in backlog mix and continued market pressure on point-of-sale project margins at the Infrastructure segment, as well as increased expenses at R2, which ramped-up operations to support the commercial launch of its Glacial products, including notable increases in salaries and benefits from headcount additions, including increased commissions for product sales as well as higher equity method losses recorded from the Company's investment in MediBeacon due to the timing of clinical trials.

(in millions)			Three Months E	nded September 30	l,		Nine Months Ended September 30,					
	2021		2020		Increase / (Decrease)		2021		2020		Increase/(Decrease)	
Infrastructure	\$	24.4	\$	17.7	\$	6.7	\$	49.6	\$	45.8	\$	3.8
Life Sciences		(7.1)		(5.9)		(1.2)		(19.4)		(14.6)		(4.8)
Spectrum		1.8		(0.2)		2.0		5.3		(2.4)		7.7
Non-operating Corporate		(3.8)		(3.7)		(0.1)		(13.5)		(12.3)		(1.2)
Other and Eliminations		(1.0)		(0.1)		(0.9)		(0.2)		(1.0)		0.8
Total Adjusted EBITDA	\$	14.3	\$	7.8	\$	6.5	\$	21.8	\$	15.5	\$	6.3

[•] Balance Sheet: As of September 30, 2021, INNOVATE had cash and cash equivalents of \$55.5 million compared to \$43.8 million as of December 31, 2020. On a stand-alone basis, as of September 30, 2021, the Corporate segment had cash and cash equivalents of \$31.6 million compared to \$27.5 million at December 31, 2020.

Conference Call

INNOVATE will host a live conference call to discuss its third quarter 2021 financial results and operations today at 4:30 p.m. ET. The Company will post an earnings supplemental presentation in the Investor Relations section of the INNOVATE website at <u>innovate-ir.com</u>, to accompany the conference call. Dial-in instructions for the conference call and the replay follows.

• Live Webcast and Call. A live webcast of the conference call can be accessed by interested parties through the Investor Relations section of the INNOVATE website at innovate-incom.

- Dial-in: 1-800-763-5545 (Domestic Toll Free) / 1-212-231-2901 (Toll/International)
- Participant Entry Number: 21998656
- <u>Conference Replay*</u>
 - Dial-in: 1-844-512-2921 (Domestic Toll Free) / 1-412-317-6671 (Toll/International)
 - Conference Number: 21998656
- *Available approximately two hours after the end of the conference call through November 18, 2021.

About INNOVATE Corp.

INNOVATE Corp., is a portfolio of best-in-class assets in three key areas of the new economy – Infrastructure, Life Sciences and Spectrum. Dedicated to stakeholder capitalism, INNOVATE employs over 4,300 people across its subsidiaries. For more information, please visit: www.INNOVATECorp.com.

Contacts

Investor Contact: Anthony Rozmus ir@innovatecorp.com (212) 235-2691

Media Contact:

Reevemark Paul Caminiti/Pam Greene/Luc Herbowy INNOVATE.Team@reevemark.com (212) 433-4600

Non-GAAP Financial Measures

In this press release, INNOVATE refers to certain financial measures that are not presented in accordance with U.S. generally accepted accounting principles ("GAAP"), including Total Adjusted EBITDA (excluding discontinued operations) and Adjusted EBITDA for its operating segments.



Adjusted EBITDA

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization's operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company's ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance. Adjusted EBITDA excludes the results of operations and any consolidating eliminations of our Insurance seement.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) as adjusted for discontinued operations; depreciation and amortization; Other operating (income) expense, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, asset impairment expense and FCC reimbursements; interest expense; net gain (loss) on contingent consideration; loss on early extinguishment or restructuring of debt; other (income) expense, net; foreign currency transaction (gain) loss included in cost of revenue; income tax (benefit) expense; noncontrolling interest; bonus to be settled in equity; share-based compensation expense; non-recurring items; costs associated with the COVID-19 pandemic, and acquisition and disposition costs.

Management recognizes that using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other GAAP financial measures, as these non-GAAP measures exclude certain items, including items that are recurring in nature, which may be meaningful to investors.

Cautionary Statement Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, "forward-looking statements." Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words "believes," "expects," "intends," "anticipates," "plans," "seeks," "estimates," "projects," "may," "will," "could," "might," or "continues" or similar expressions. Such forward-looking statements are based on current expectations and inherently involve certain risks, assumptions and uncertainties. The forward-looking statements in this presentation include, without limitation, any statements regarding INNOVATE's inability to predict the extent to which the COVID-19 pandemic and related impacts will continue to adversely impact INNOVATE's business operations, financial performance, results of operations, financial position, the prices of INNOVATE's securities and the achievement of INNOVATE's strategic objectives, and changes in macroeconomic and market conditions and market volatility (including developments and volatility arising from the COVID-19 pandemic), including interest rates, the value of securities and other financial assets, and the impact of such changes and volatility on INNOVATE's financial position. Such statements are based on the beliefs and assumptions of INNOVATE's management and the management of INNOVATE's subsidiaries and portfolio companies.

The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance, results or the creation of stockholder value and the Company's actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, including those that may be identified in subsequent statements and reports filed with the Securities and Exchange Commission ("SEC"), including in our reports on Forms 10-K, 10-Q, and 8-K. Such important factors include, without limitation: the severity, magnitude and duration of the COVID-19 pandemic, including impacts of the pandemic and of businesses' and governments' responses to the pandemic on INNOVATE's operations and personnel, and on commercial activity and demand across our businesses, capital market conditions, including the ability of INNOVATE and INNOVATE's subsidiaries to raise capital; the ability of INNOVATE's subsidiaries and portfolio companies to generate sufficient net income and cash flows to make upstream cash distributions; volatility in the trading price of INNOVATE common stock; the ability of INNOVATE and its subsidiaries and portfolio companies to identify any suitable future acquisition or disposition opportunities; our ability to realize efficiencies, cost savings, income and margin improvements, growth, economies of scale and other anticipated benefits of strategic transactions; difficulties related to the integration of financial reporting of acquired or target businesses; difficulties completing pending and future acquisitions and dispositions; effects of litigation, indemnification claims, and other contingent liabilities; changes in regulations and tax laws; and risks that may affect the performance of the operating subsidiaries and portfolio companies of INNOVATE.

Although INNOVATE believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. These risks and other important factors discussed under the caption "Risk Factors" in our most recent Annual Report on Form 10-K filed with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation.

You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to INNOVATE or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, INNOVATE undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INNOVATE CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) (Unaudited)

	Three Months End	led September 30,		Nine Months End	led Septembe	er 30,
	 2021	2020		2021		2020
Revenue	\$ 394.8	\$ 170.5	\$	810.4	\$	538.9
Cost of revenue	339.7	138.8		688.4		447.7
Gross profit	55.1	31.7		122.0		91.2
Operating expenses:						
Selling, general and administrative	44.3	33.9		120.9		109.2
Depreciation and amortization	8.9	4.5		17.6		13.3
Other operating loss	0.8	9.4		1.0		7.3
Income (loss) from operations	1.1	(16.1)	(17.5)		(38.6)
Other (expense) income:						
Interest expense	(12.8)	(17.9)	(46.6)		(56.2)
Loss on early extinguishment or restructuring of debt	(0.1)	_		(12.5)		(9.2)
Loss from equity investees	(2.9)	(1.3)	(4.8)		(4.0)
Other income	0.6	6.9		4.4		73.0
Loss from continuing operations before income taxes	 (14.1)	(28.4)	(77.0)		(35.0)
Income tax expense	(0.1)	(1.4)	(3.8)		(3.7)
Loss from continuing operations	(14.2)	(29.8)	(80.8)		(38.7)
(Loss) income from discontinued operations (including loss on sale of \$200.3 million for the three months ended September 30, 2021 and net loss on sales of \$159.9 million and \$39.3 million for the nine months ended September 30, 2021 and 2020, respectively)	(200.3)	8.2		(149.9)		(55.4)
Net loss	 (214.5)	(21.6)	(230.7)		(94.1)
Net loss attributable to noncontrolling interest and redeemable noncontrolling interest	2.6	4.3		7.9		6.8
Net loss attributable to INNOVATE Corp.	(211.9)	(17.3)	(222.8)		(87.3)
Less: Preferred dividends and deemed dividends from conversions	1.1	0.4		1.7		1.2
Net loss attributable to common stock and participating preferred stockholders	\$ (213.0)	\$ (17.7) \$	(224.5)	\$	(88.5)
	 	· · · · · · · · · · · · · · · · · · ·				
Loss per common share - continuing operations						
Basic	\$ (0.16)	\$ (0.57) \$	(0.98)	\$	(1.06)
Diluted	\$ (0.16)	\$ (0.57) \$	(0.98)	\$	(1.06)
				((
Loss per common share - discontinued operations						
Basic	\$ (2.59)	\$ 0.20	\$	(1.94)	\$	(0.83)
Diluted	\$ (2.59)	\$ 0.20	\$	(1.94)	\$	(0.83)
Loss per share - Net loss attributable to common stock and participating preferred stockholders						
Basic	\$ (2.75)	\$ (0.37) \$	(2.92)	\$	(1.89)
Diluted	\$ (2.75)	\$ (0.37) \$	(2.92)	\$	(1.89)
Weighted average common shares outstanding:						
Weighted average common shares outstanding: Basic	77.2	47.4		77.0		46.7

INNOVATE CORP. CONDENSED CONSOLIDATED BALANCE SHEET (in millions, except share amounts) (Unaudited)

	September 30, 2021		December 31, 2020
Assets			
Current assets			
Cash and cash equivalents	\$	55.5 \$	43.8
Accounts receivable, net	4	25.0	184.7
Contract assets		72.5	55.6
Inventory		17.4	9.9
Restricted cash		8.6	1.5
Assets held for sale		2.2	5,942.1
Other current assets		11.0	8.7
Total current assets	5	92.2	6,246.3
Investments		49.9	55.4
Deferred tax asset		2.8	3.0
Property, plant and equipment, net	1	58.2	112.8
Goodwill		22.8	111.0
Intangibles, net		13.1	172.1
Other assets		72.5	42.2
Total assets		21.5 \$	6,742.8
	· · · · · · · · · · · · · · · · · · ·	<u> </u>	
Liabilities, temporary equity and stockholders' (deficit) equity			
Current liabilities			
Accounts payable	\$ 1	33.2 \$	69.7
Accrued liabilities		99.7	77.1
Current portion of debt obligations		71.1	433.6
Contract potential de la configurational		51.4	52.2
Liabilities held for sale	-	_	5,306.7
Other current labilities		18.0	12.9
Total current liabilities		33.4	5,952.2
Deferred tax liability	5	8.0	7.0
Det obligations	6	0.0	127.9
Debe labilities		52.0 51.7	39.8
Oner naonnes		05.9	6,126.9
Commitments and contingencies	1,2	13.9	0,120.9
Temporary equity			
Preferred stock		19.1	10.4
Redeemable noncontrolling interest		51.2	5.3
Total temporary equity		70.3	15.7
Stockholders' (deficit) equity			
Common stock, \$0.001 par value		0.1	0.1
Shares authorized: 160,000,000 at September 30, 2021 and December 31, 2020, respectively			
Shares issued: 79,157,332 and 77,836,586 at September 30, 2021 and December 31, 2020, respectively			
Shares outstanding: 77,768,116 and 76,726,835 at September 30, 2021 and December 31, 2020, respectively	-		
Additional paid-in capital		31.2	355.7
Treasury stock, at cost: 1,389,216 and 1,109,751 shares at September 30, 2021 and December 31, 2020, respectively		(5.2)	(4.2)
Accumulated deficit	(4	11.5)	(188.7)
Accumulated other comprehensive income		3.2	396.9
Total INNOVATE Corp. stockholders' (deficit) equity		32.2)	559.8
Noncontrolling interest		27.5	40.4
Total stockholders' (deficit) equity		54.7)	600.2
Total liabilities, temporary equity and stockholders' (deficit) equity	\$ 1,2	21.5 \$	6,742.8

INNOVATE CORP. RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (Unaudited)

(in millions)	Three months ended September 30, 2021										
	In	nfrastructure	Life Sciences	Spectrum	Non-operating Corporate	Other and Eliminations	INNOVATE				
Net (loss) attributable to INNOVATE Corp.							\$ (211.9)				
Less: Discontinued operations							(200.3)				
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	\$	6.9 \$	(5.1) \$	(4.1)	\$ (8.0)	\$ (1.3)	\$ (11.6)				
Adjustments to reconcile net income (loss) to Adjusted EBITDA:											
Depreciation and amortization		7.4	_	1.4	0.1	—	8.9				
Depreciation and amortization (included in cost of revenue)		3.4	_	-	-	—	3.4				
Other operating expense		0.1	_	0.7	_	_	0.8				
Interest expense		2.2	_	2.4	8.2	_	12.8				
Other (income) expense, net		(0.3)	_	1.5	(1.8)	—	(0.6)				
Loss on early extinguishment or restructuring of debt		-	_	0.1	-	—	0.1				
Income tax expense (benefit)		2.9	_	-	(2.8)	—	0.1				
Noncontrolling interest		0.7	(2.0)	(0.9)	-	(0.4)	(2.6)				
Share-based compensation expense		_	_	0.3	0.1	_	0.4				
Nonrecurring Items		(0.1)	_	-	-	—	(0.1)				
COVID-19 Costs		0.4	_	-	_	—	0.4				
Acquisition and disposition costs		0.8	_	0.4	0.4	0.7	2.3				
Adjusted EBITDA	\$	24.4 \$	(7.1) \$	1.8	\$ (3.8)	\$ (1.0)	\$ 14.3				

(in millions)				Three months ended	September 30, 2020			
	Infrastructure		Life Sciences	Spectrum	Non-operating Corporate	Other and Eliminations	INNOVA	TE
Net (loss) attributable to INNOVATE Corp.							\$	(17.3)
Less: Discontinued operations								8.2
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	\$	2.4	\$ (4.3)	\$ (14.6)	\$ (8.0)	\$ (1.0)	\$	(25.5)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:								
Depreciation and amortization		2.7	_	1.7	0.1	_		4.5
Depreciation and amortization (included in cost of revenue)		2.3	-	-	-	_		2.3
Other operating (income) expense		(0.3)	0.1	9.6	-	—		9.4
Interest expense		2.1	_	3.6	12.2	_		17.9
Other (income) expense, net		(0.1)	0.1	0.3	(7.2)	_		(6.9)
Income tax expense (benefit)		1.5	_	_	(2.3)	2.2		1.4
Noncontrolling interest		0.1	(1.8)	(1.1)	-	(1.5)		(4.3)
Bonus to be settled in equity		-	-	-	(0.2)	_		(0.2)
Share-based compensation expense		_	_	0.2	0.7	_		0.9
Nonrecurring Items		0.4	_	_	0.2			0.6
COVID-19 Costs		6.4	_	_	_	_		6.4
Acquisition and disposition costs		0.2	_	0.1	0.8	0.2		1.3
Adjusted EBITDA	\$	17.7	\$ (5.9)	\$ (0.2)	\$ (3.7)	\$ (0.1)	\$	7.8

INNOVATE CORP. RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA (Unaudited)

(in millions)	Infrastru	chure	Life Sciences	Spectrum	ed September 30, 2021 Non-operating Corporate	Other and Eliminations	INNOVATE	VATE
Net (loss) attributable to INNOVATE Corp	IIIIasciu	citile	Life Sciences	Speculum	Non-operating Corporate	Other and Emmacions		(222.
Less: Discontinued operations								(149.
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	S	8.3 \$	(13.6)	\$ (96) \$ (58.0)	s —		(72.
Adjustments to reconcile net income (loss) to Adjusted EBITDA:	Ŷ	0.5 \$	(15.0)	÷ (5.	, , , , , , , , , , , , , , , , , , , ,	9	Ŷ	(/ 2
Depreciation and amortization		13.1	0.1	4.3	0.1	_		17.
Depreciation and amortization (included in cost of revenue)		8.4	_	_		_		8.
Other operating expenses		0.1	_	0.9		_		1.
Interest expense		6.3	-	7.1	33.2	-		46.
Other (income) expense, net		(4.2)	-	2.3	(2.5)	_		(4.4
Loss on early extinguishment or restructuring of debt		1.5	-	1.0		-		12.
Income tax expense (benefit)		4.1	-	_	(0.3)	_		3.
Noncontrolling interest		0.9	(6.0)	(1.9) –	(0.9)		(7.9
Share-based compensation expense		_	0.1	0.6		-		1.5
Nonrecurring Items		0.3	_	-	0.5	_		0.8
COVID-19 Costs		8.3	_	-		_		8.
Acquisition and disposition costs		2.5	-	0.6	2.5	0.7		6.
Adjusted EBITDA	S	49.6 \$	(19.4)	\$ 5.3	\$ (13.5)	\$ (0.2)	\$	21.
(in millions)					ed September 30, 2020			
	Infrastructure		Life Sciences	Nine months end Spectrum	ed September 30, 2020 Non-operating Corporate	Other and Eliminations	INNOVATE	
Net (loss) attributable to INNOVATE Corp	Infrastructure		Life Sciences			Other and Eliminations	\$	(87.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations				Spectrum	Non-operating Corporate		\$	(87. (55.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	Infrastructure \$	4.0 \$		Spectrum	Non-operating Corporate		\$	(87. (55.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA;			(8.7)	Spectrum \$ (23.8	Non-operating Corporate) \$ (72.0)		\$	(87. (55. (31.)
Ver (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) Io Adjusted EBITDA; Depreciation and amortization		8.0		Spectrum	Non-operating Corporate) \$ (72.0)		\$	(87. (55. (31.) 13.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization (included in cost of revenue)		8.0 6.9	(8.7) 0.1	Spectrum \$ (23.6	Non-operating Corporate) \$ (72.0) . 0.1 .		\$	(87. (55. (31.) 13. 6.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization (included in cost of revenue) Other operating (income) expenses		8.0 6.9 (0.2)	(8.7)	Spectrum	Non-operating Corporate Non-operating Corporate S (72.0) 0.1		\$	(87. (55. (31.) 13. 6. 7.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization Depreciation and amortization (included in cost of revenue) Other operating (income) expenses Interest expense		8.0 6.9 (0.2) 6.5	(8.7) 0.1 0.1	Spectrum \$ (23.6 5. - 7.4. 10.3	Non-operating Corporate Non-operating Corporate (72.0) 0.1	\$ 68.6 	\$	(87.) (55.) (31.) 13. 6.) 7. 56.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization (included in cost of revenue) Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt		8.0 6.9 (0.2) 6.5 —	(8.7) 0.1 0.1 	Spectrum \$ (23.6 5.7 - 7.4 10.7 -	Non-operating Corporate) \$ (72.0) -	\$ 68.6 	\$	(87 (55 (31.) 13. 6. 7. 56. 9.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net		8.0 6.9 (0.2) 6.5 —	(8.7) 0.1 	Spectrum \$ (23.6 7.4 10.1 1.3	Non-operating Corporate) \$ (72.0)	\$ 68.6 	\$	(87 (55 (31.) 13. 6. 7. 56. 9. (73.0
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net Income tax (benefit) expense		8.0 6.9 (0.2) 6.5 — — 2.5	(8.7) 0.1 0.1 (2.2) 	Spectrum	Non-operating Corporate Non-operating Corporate \$ 0.1 - - - - - - - 9.2 - 0.8) - 1.6	\$ 68.6 (71.3) (0.4)	\$	(87 (55 (31.) 13. 6. 7. 56. 9. (73.) (73.) 3.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization (included in cost of revenue) Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net Income tax (benefit) expenses Interest expense		8.0 6.9 (0.2) 6.5 — 2.5 0.2	(8.7) 0.1 	Spectrum	Non-operating Corporate) \$ (72.0) -	\$ 68.6 	\$	(87 (55 (31.) 13. 6. 7. 56. 9. (73.) (73.) (6.)
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation and amortization Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net Income tax (benefit) expense Noncontrolling interest Bonus to be settled in equity		8.0 6.9 (0.2) 6.5 2.5 0.2 	(8.7) 0.1 	Spectrum	Non-operating Corporate) \$ (72.0) . 0.1 	\$ 68.6 	\$	(87.: (55.4 (31.9) 13. 6. 7. 56. 9. (73.1 (73.1) 3. (6.4) (0.9)
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amoritzation Depreciation and amoritzation Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net Income tax (benefit) expense Noncontrolling interest Bonus to be settled in equity Share-based compensation expense		8.0 6.9 (0.2) 6.5 — 2.5 0.2 — —	(8.7) 0.1 (2.2) (4.0) 0.1	Spectrum	Non-operating Corporate Non-operating Corporate \$ (72.0) . 0.1 	\$ 68.6 	\$	(87. (55. (31.) 13. 6. 7. 56. 9. (73. (73. 3. (6.) (0. 2.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net Income tax (benefit) expense Noncontrolling interest Bonus to be settled in equity Share-based compensation expense Nonrecurring Items		8.0 6.9 (0.2) 6.5 2.5 0.2 2.2	(8.7) 0.1 	Spectrum	Non-operating Corporate) \$ (72.0) . 0.1 . 0.1 . . .	\$ 68.6 	\$	(87. (55. (31.) 13. 6. 7. 56. 9. (73.) (73.) (6.) (0. 2. 7.
Net (loss) attributable to INNOVATE Corp Less: Discontinued operations Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations Adjustments to reconcile net income (loss) to Adjusted EBITDA: Depreciation and amortization Depreciation and amortization Interest Represe Nonrecurring Items CovUID-19 Costs		8.0 6.9 (0.2) 6.5 2.5 0.2 2.2 15.2	(8.7) 0.1 	Spectrum	Non-operating Corporate) \$ (72.0) . 0.1 . . . <	\$ 68.6 	\$	(87. (55. (31.) 13. 6. 7. 56. 9. (73.) (73.) (73.) (6. (0. 2. 7. 15.
Depreciation and amortization (included in cost of revenue) Other operating (income) expenses Interest expense Loss on early extinguishment or restructuring of debt Other (income) expense, net Income tax (benefit) expense Noncontrolling interest Bonus to be settled in equity Share-based compensation expense Nonrecurring Items		8.0 6.9 (0.2) 6.5 2.5 0.2 2.2	(8.7) 0.1 	Spectrum	Non-operating Corporate Non-operating Corporate \$ (72.0) .	\$ 68.6 	\$	(87. (55. (31. 13. 6. 7. 56. 9. (73. 3. (6. (0. 2. 7.



INNOVATE Corp.

Q3 2021 Earnings Release Supplement

November 4, 2021

© INNOVATE Corp. 2021

Safe Harbor Disclaimers



Cautionary Statement Regarding Forward-Looking Statements

Cautionary Statement Regarding Porward-Looking Statements Safe Harbor Statement under the Private Socurities Lingtainon Reform Act of 1995: This presentation contains, and certain oral statements made by our representatives from time to time may contain, "forward-looking statements." Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words "believes," "expects," "intends," "anticipates," "plans, "seeks," "estimates, "projects," "may," will," "could," might," or "continues" or similar expressions. Such forward-looking statements are based on current expectations and inherently involve certain risks, assumptions and uncertainties. The forward-looking statements include, without limitation, any statements regarding our inability to predict the extent to which the COVID-19 pandemic and related impacts will continue to adversely impact INNOVATE's business operations, financial performance, results of operations, financial position, the prices of INNOVATE's sourcement of INNOVATE's strategic objectives, and changes in macroeconomic and market conditions and market volatility (including developments and volatility arising from the COVID-19 pandemic), including interest rates, the value of securities and ther financial assets, and the impact of stude changes and volatility on INNOVATE's financial position. Such statements are based on the beliefs and assumptions of INNOVATE's management and the management of INNOVATE's subsidiaries and portfolio companies.

INNOVATE believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance, results or the creation of stockholder value and our actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, including those that may be identified in subsequent statements and reports filed with the Securities and Exchange Commission ("SEC"), including in our reports on Forms 10-K, 10-Q, and 8-K. Such important factors include, without limitation: the severity, magnitude and duration of the COVID-19 pandemic, including indemic and ob businesses' and governments' responses to the pandemic on INNOVATE's operations and personnel, and on commercial activity and demand across our businesses, capital market conditions, including the ability of INNOVATE and INNOVATE's operations and personnel, and on commercial activity and demand across our businesses, capital market conditions, including the ability of INNOVATE and INNOVATE's operations of portfolic companies to generate sufficient net income and cash flows to make upstream cash distributions; volatility in the trading price of INNOVATE common stock; the ability of INNOVATE and its subsidiaries and portfolic companies to generate subicidenties of strategic transactions; difficulties related to the integration of financial reporting of acquired or target businesses; auxies, income and margin improvements, growth, economise of scale and other anticipated benefits of strategic transactions; difficulties completing pending and future acquisitions; effects of litigation, indemnification claims, and other contingent liabilities; changes in regulations and tax and strate activations of the operating subsidiaries and portfolic companies of litigation; alternation of litigation, indemnification claims, and other contingent liabilities; changes in regulations and tax any affect the performance of the operating subsidiaries and por

Although INNOVATE believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. These risks and other important factors discussed under the caption "Risk Factors" in our most recent Annual Report on Form 10-K filed with the SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation.

You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to INNOVATE or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, INNOVATE undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

© INNOVATE Corp. 2021

Safe Harbor Disclaimers



Non-GAAP Financial Measures

In this earnings release supplement, INNOVATE refers to certain financial measures that are not presented in accordance with U.S. generally accepted accounting principles ("GAAP"), including Adjusted EBITDA, which excludes results for discontinued operations, and Adjusted EBITDA for its operating segments.

Adjusted EBITDA

Adjusted EBITDA is not a measurement recognized under U.S. GAAP. In addition, other companies may define Adjusted EBITDA differently than we do, which could limit its usefulness.

Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization's operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company's ability to service debt. While management believes that non-U.S. GAAP measurements are useful supplemental information, such adjusted results are not intended to replace our U.S. GAAP financial results. Using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other U.S. GAAP financial measures, as this non-GAAP measure excludes certain items, including items that are recurring in nature, which may be meaningful to investors. As a result of the exclusions, Adjusted EBITDA should not be considered in isolation and does not purport to be an alternative to net income (loss) or other U.S. GAAP financial measures as a measure of our operating performance. Adjusted EBITDA excludes the results of operations and any consolidating eliminations of our insurance segment.

The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) as adjusted for discontinued operations; depreciation and amortization; Other operating (income) expense, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, asset impairment expense and FCC reimbursements; interest expense; net gain (loss) on contingent consideration; loss on early extinguishment or restructuring of debt; gain (loss) on sale of subsidiaries; other (income) expense, net; foreign currency transaction (gain) loss included in cost of revenue; income tax (benefit) expense; noncontortalling interest; bonus to be settled in equity; share-based compensation expense; non-recurring items; costs associated with the COVID-19 pandemic and acquisition and disposition costs.

Third Party Sources

Third party information presented in this earnings release supplement is based on sources we believe to be reliable, however there can be no assurance information so presented will prove accurate in whole or in part.

© INNOVATE Corp. 2021



DBM maintains backlog levels while converting revenue R2 earns milestone key FDA approval for Glacial Rx Spectrum achieves profitability for fourth consecutive quarter

INNOVATE

- Closed the sale of Continental General Holdings (Insurance segment)
- Infused R2 Technologies with \$15 million in Series C funding to continue rollout and development
- R2 Technologies' Novel Glacial Rx® System Earned Third FDA Indication and Unique Product Code
- Completed name change to INNOVATE Corp. and started trading under the symbol "VATE"

© INNOVATE Corp. 2021

Segment Highlights



	Pansed Life Sciences	HC2 Broadcasting						
Infrastructure Highlights	Life Sciences Highlights	Spectrum Highlights						
 Reported Backlog = \$1,606M Total adjusted backlog⁽ⁱ⁾ = \$1,889M Converting backlog to revenue while maintaining backlog levels 	 Infused R2 with \$15 million to continue the rollout and development of its products. 	 Net Loss of \$4.1M, and Adjusted EBITDA⁽²⁾ of \$1.8M Spectrum year-to-date 9/30/2021 Adjusted EBITDA⁽²⁾ of \$5.3M 						
 Backlog provides runway for growth in 2022 and beyond Banker Steel making an immediate impact to DBM Poised to benefit from Infrastructure Bill, directly or indirectly 	 Glacial Rx[®] earns third FDA indication, becoming the first and only Class II dermal cooling system FDA-cleared for dermabrasion MediBeacon 	 Reached an agreement with Cisneros Media to launch Novelisima Increased the distribution of beIN EXTRA Sports networks 						
 Adjusted Backlog takes into consideration awarded, but not yet signed contracts. See Appendix for reconciliation of Non-GAAP to U.S. GAAP. 	 In dialogue with the FDA regarding commencement of U.S. Pivotal Study NNOVATE Corp. 2021 	 83 Networks using the HC2 platform 						

Q3 2021 Financial Highlights




			_	_	_	Consolidated Q3 Results
Revenue						Revenue increased \$224.3M or 131.6% driven by our Infrastructure segment, due primarily to DBM's
(\$ millions)		3Q21		3Q2	0	recent acquisition of Banker Steel and increases across the DBM platform
Infrastructure	\$		383.0	i i	160.8	 Net Loss attributable to common stock and participating preferred stockholders of \$213.0M, drive mainly by the loss on the sale of the Insurance segment
Life Sciences			1.6			 Adjusted EBITDA increased to \$14.3M, or \$6.5M driven by contribution from Banker Steel at
Spectrum			10.2		9.7	Infrastructure combined with higher station revenues and cost savings at Spectrum
Consolidated INNOVATE	\$		394.8		170.5	Infrastructure
						Net Income of \$6.9M
Net Income Attrib. to) INI	NOVATE	Corp. &	Adj. EBIT	DA	 \$24.4M in Adjusted EBITDA; contracted backlog of \$1,605.9M (Adjusted ~\$1,889M⁽³⁾), compared to \$394.5M at 12/31/20
		3Q21		3Q2	0	
						Sportrum
(\$ millions)	-	100222-014	Adj. ITDA ⁽²⁾	NI ⁽¹⁾	Adj. EBITDA ⁽²⁾	Spectrum Net Loss of \$4.1M
(\$ millions) Infrastructure	\$	100222-014	Adj. IITDA ⁽²⁾ 24.4			
	\$	NI ⁽¹⁾ EB				■ Net Loss of \$4.1M
Infrastructure	\$	NI ⁽¹⁾ EB	24.4	2.4 \$	17.7	 Net Loss of \$4.1M \$1.8M in Adjusted EBITDA
Infrastructure Life Sciences	\$	NI ⁽¹⁾ EB 6.9 \$ (5.1)	24.4 \$ (7.1)	i 2.4 s (4.3)	17.7 (5.9)	 Net Loss of \$4.1M \$1.8M in Adjusted EBITDA Fourth consecutive quarter of positive Adjusted EBITDA contribution Life Sciences Glacial Rx became FDA-cleared to remove benign lesions and temporarily reduce pain, swelling an
Infrastructure Life Sciences Spectrum Non-operating Corporate	\$	NI ⁽¹⁾ EB 6.9 \$ (5.1) (4.1)	24.4 \$ (7.1) 1.8	(4.3) (14.6)	17.7 (5.9) (0.2)	Net Loss of \$4.1M \$1.8M in Adjusted EBITDA Fourth consecutive quarter of positive Adjusted EBITDA contribution Life Sciences Glacial Rx became FDA-cleared to remove benign lesions and temporarily reduce pain, swelling an inflammation; is now the first and only Class II dermal cooling system FDA-cleared for general
Infrastructure Life Sciences Spectrum	\$	NI ⁽¹⁾ EB 6.9 \$ (5.1) (4.1) (8.0)	24.4 \$ (7.1) 1.8 (3.8)	i 2.4 \$ (4.3) (14.6) (8.0) (1.0)	(5.9) (0.2) (3.7) (0.1)	 Net Loss of \$4.1M \$1.8M in Adjusted EBITDA Fourth consecutive quarter of positive Adjusted EBITDA contribution Life Sciences Glacial Rx became FDA-cleared to remove benign lesions and temporarily reduce pain, swelling an inflammation; is now the first and only Class II dermal cooling system FDA-cleared for gener. dermabrasion, scar and acre scar revision, and tatkoo removal MediBeacon preparing for its Pivotal Clinical Study for use of the TGFR system for renal monitoring
Infrastructure Life Sciences Spectrum Non-operating Corporate Other & Eliminations Consolidated INNOVATE,	\$ \$	NI ⁽¹⁾ EB 6.9 \$ (5.1) (4.1) (8.0) (1.3)	24.4 \$ (7.1) 1.8 (3.8) (1.0)	i 2.4 \$ (4.3) (14.6) (8.0) (1.0) (25.5) \$	(5.9) (0.2) (3.7) (0.1)	 Net Loss of \$4.1M \$1.8M in Adjusted EBITDA Fourth consecutive quarter of positive Adjusted EBITDA contribution Life Sciences Glacial Rx became FDA-cleared to remove benign lesions and temporarily reduce pain, swelling an inflammation; is now the first and only Class II dermal cooling system FDA-cleared for gener. dermabrasion, scar and acre scar revision, and tatkoo removal MediBeacon preparing for its Pivotal Clinical Study for use of the TGFR system for renal monitorin (potentially Q1 2022)
Infrastructure Life Sciences Spectrum Non-operating Corporate Other & Eliminations Consolidated INNOVATE, Excluding Disc Ops	\$ \$ \$ \$	NI(**) EB 6.9 \$ (5.1) (4.1) (6.0) (1.3) (1.3)	24.4 \$ (7.1) 1.8 (3.8) (1.0) 14.3 \$	i 2.4 \$ (4.3) (14.6) (8.0) (1.0) i (25.5) \$ i 8.2	(5.9) (0.2) (3.7) (0.1)	 Net Loss of \$4.1M \$1.8M in Adjusted EBITDA Fourth consecutive quarter of positive Adjusted EBITDA contribution Life Sciences Glacial Rx became FDA-cleared to remove benign lesions and temporarily reduce pain, swelling an inflammation; is now the first and only Class II dermal cooling system FDA-cleared for gener. dermabrasion, scar and acre scar revision, and tatkoo removal MediBeacon preparing for its Pivotal Clinical Study for use of the TGFR system for renal monitoring

(1) Net income attributable to INNOVATE Corp.
 (2) See Appendix for reconciliation of Non-GAAP to U.S. GAAP.
 (3) Adjusted Backlog takes into consideration awarded, but not yet signed contracts.

© INNOVATE Corp. 2021

Current Credit Picture

Debt Summary					
(\$ millions)	Maturity	S	Sep-21	C	ec-20
11.50% Senior Secured Notes	2021	\$	-	\$	340.4
8.50% Senior Secured Notes	2026		330.0		1.
7.50% Convertible Senior Notes	2022		3.2		55.0
7.50% Convertible Senior Notes	2026		51.8		_
Line of Credit ⁽¹⁾	2024		5.0		15.0
Infrastructure Debt	Various		231.6		110.5
Spectrum Debt	Various		54.4		55.7
Total Principal Outstanding		\$	676.0	\$	576.6
Unamortized OID and DFC			(2.1)		(15.1)
Total Debt		\$	673.9	\$	561.5
Cash & Cash Equivalents (2)			55.5		43.8
Net Debt		\$	618.4	\$	517.7



(1) Borrowing rate on Line of Oredit reduced from LIBOR plus 6.75% to LIBOR plus 5.75% in February 2021. (2) Excludes cash included in Discontinued Operations. (3) Doth Maluffy Profile excludes Prevender Stock and capital leases (4) infrastructure Line of Credit reflects maturity in 2024 and not U.S. GAAP presentation. (5) Profermo Educ Profile for Spectrum edit Intuit ava starting of Credit Profile Stock and 2022.

© INNOVATE Corp. 2021





Segment Highlights - Infrastructure

DBM Global ("DBM")

Overview

- 138.2% revenue increase due to the acquisition of Banker Steel as well as higher revenues across DBM's service offering
- Adjusted EBITDA increase can be attributed by the contribution from Banker Steel, partially offset by margin compression at the DBM legacy businesses
- Reported backlog level of \$1.6B maintained from last quarter
- Taking into consideration awarded but not yet signed contracts, adjusted backlog was ~\$1.9B; provides visibility into 2022 and beyond

Near-Term Focus

 Well-positioned to take advantage of rebounding commercial and industrial construction markets, and opportunities from potential federal infrastructure spending Financials

(\$ millions)	3	3Q21	3Q20		
Revenue	\$	383.0	\$	160.8	
Net Income	\$	6.9	\$	2.4	
Adjusted EBITDA (1)	\$	24.4	\$	17.7	

Trending Backlog



See Appendix for reconciliation of Non-GAAP to U.S. GAAP.
 All data as of September 30, 2021 unless otherwise noted.

© INNOVATE Corp. 2021



Segment Highlights - Life Sciences

Pansend Life Sciences ("Pansend")

R2 Technologies

- Received \$15M Series C funding through INNOVATE's subsidiary Pansend to continue their revenue-driving phase following the commercial launch of Glacial Rx[®], and more broadly to support their development of innovative technologies and global expansion
- Glacial Rx[®]
 - Earns third FDA indication and unique product code
 The launch of commercial shipments to U.S. aesthetic providers for Glacial Rx[®] continues as planned
- Glacial SpaTM

 Decided to delay the launch, which has been impacted by the global supply chain issues

Summary of Investments

R2

MediBeacon

Company	Investment to Date	Equity %	Fully Diluted %
R2 Technologies	\$42.4M	56.3%	51.3%
MediBeacon	\$24.9M	47.2%	41.6%
Genovel	\$3.8M	80.0%	75.2%
Triple Ring	\$3.0M	25.8%	22.9%

Investment-to-date totals and equity ownership percentages are as of September 30, 2021.
 MediBeacon agents and devices are not approved for human use by any regulatory agency.

© INNOVATE Corp. 2021

9

 (\mathbf{Q})

Remains in dialogue with FDA regarding the commencement for the U.S. Pivotal Study, which is hopeful to begin in the fourth quarter
Global Pivotal Study expanded to include China, starts in early 2022
Gastrointestinal Health - Current permeability study ongoing with 20 patients

MediBeacon

Segment Highlights - Spectrum

HC2 Broadcasting ("Broadcasting")

Overview

- Fourth consecutive quarter of positive Adjusted EBITDA contribution
- Reached an agreement with Cisneros Media to launch Novelisima September, a new Spanish language network that broadcasts telenovelas in more than 70 markets in the US on our platform
- Increased the distribution of beIN EXTRA Sports networks, which are 24/7 live sports channels offered in both English and Spanish, offering the most comprehensive free ad-supported live sports programming "over the air". Nationwide, broadcasts beIN Sports on more than 120 channels in over 60 markets
- 83 networks air on HC2's platform as of September 2021


Near-Term Focus

- Continue business development and sign up large content providers; strong pipeline of pending lease agreements or revenue shares across multiple markets
- Expect 24 new station builds to be completed by Q1 2022
- Explore ATSC 3.0 technologies that offer expanded capability and use of Broadcasting's spectrum

Financials

(\$ millions)	3	Q21	3Q20
Station Group	\$	4.7	\$ 4.1
Network ("Azteca")		5.5	5.6
Revenue	\$	10.2	\$ 9.7
Net Loss	\$	(4.1)	\$ (14.6)
Adjusted EBITDA (1)	\$	1.8	\$ (0.2)

Station Growth



(1) See Appendix for reconciliation of Non-GAAP to U.S. GAAP.

reconciliation of Non-GAAP to U.S. GAAP.



Appendix

Select GAAP Financials & Non-GAAP Reconciliations

© INNOVATE Corp. 2021

INNOVATE Selected GAAP Financials

Income Statement - Unaudited



(in millions)	Th	ree months ended	September 30,	Nin	e months ended S	eptember 30,
		2021	2020		2021	2020
Revenue	\$	394.8 \$	170.5	\$	810.4 \$	538.9
Cost of revenue		339.7	138.8		688.4	447.7
Gross profit		55.1	31.7	0.0	122.0	91.2
Operating expenses:						
Selling, general and administrative		44.3	33.9		120.9	109.2
Depreciation and amortization		8.9	4.5		17.6	13.3
Other operating loss		0.8	9.4		1.0	7.3
Income (loss) from operations		1.1	(16.1)		(17.5)	(38.6
Other (expense) income:						
Interest expense		(12.8)	(17.9)		(46.6)	(56.2
Loss on early extinguishment or restructuring of debt		(0.1)	—		(12.5)	(9.2
Loss from equity investees		(2.9)	(1.3)		(4.8)	(4.0
Other income	-	0.6	6.9		4.4	73.0
Loss from continuing operations before income taxes		(14.1)	(28.4)		(77.0)	(35.0
Income tax expense		(0.1)	(1.4)	<u>(</u>	(3.8)	(3.7
Loss from continuing operations		(14.2)	(29.8)		(80.8)	(38.7
(Loss) income from discontinued operations (including loss on sale of \$200.3 million for the three months ended September 30, 2021 and net loss on sales of \$159.9 million and \$39.3 million for the						
nine months ended September 30, 2021 and 2020, respectively)		(200.3)	8.2		(149.9)	(55.4
Net loss		(214.5)	(21.6)		(230.7)	(94.1
Net loss attributable to noncontrolling interest and redeemable noncontrolling interest	_	2.6	4.3		7.9	6.8
Net loss attributable to INNOVATE Corp.		(211.9)	(17.3)		(222.8)	(87.3
Less: Preferred dividends and deemed dividends from conversions		1.1	0.4		1.7	1.2
Net loss attributable to common stock and participating preferred stockholders	\$	(213.0) \$	(17.7)	\$	(224.5) \$	(88.5

© INNOVATE Corp. 2021

(in millions)			Th	ree	months ended	September 30, 2	Three months ended September 30, 2021										
	Infrastructure		 Life Sciences		Spectrum	Non-operating Corporate	Other and Eliminations	INNOVATE									
Net (loss) attributable to INNOVATE Corp.	10							\$	(211.9)								
Less: Discontinued operations								_	(200.3)								
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	\$	6.9	\$ (5.1)	\$	(4.1)	\$ (8.0)	\$ (1.3)	\$	(11.6)								
Adjustments to reconcile net income (loss) to Adjusted EBITDA:																	
Depreciation and amortization		7.4	_		1.4	0.1	-		8.9								
Depreciation and amortization (included in cost of revenue)		3.4			_				3.4								
Other operating expense		0.1	_		0.7	_			0.8								
Interest expense		2.2	_		2.4	8.2			12.8								
Other (income) expense, net		(0.3)	—		1.5	(1.8)			(0.6)								
Loss on early extinguishment or restructuring of debt		_	_		0.1		_		0.1								
Income tax expense (benefit)		2.9	_		_	(2.8)	_		0.1								
Noncontrolling interest		0.7	(2.0)		(0.9)	_	(0.4)		(2.6)								
Share-based compensation expense			-		0.3	0.1	_		0.4								
Nonrecurring Items		(0.1)	_			<u> </u>			(0.1)								
COVID-19 Costs		0.4	_		_		_		0.4								
Acquisition and disposition costs		0.8	_		0.4	0.4	0.7		2.3								
Adjusted EBITDA	\$	24.4	\$ (7.1)	\$	1.8	\$ (3.8)	\$ (1.0)	\$	14.3								

© INNOVATE Corp. 2021

(in millions)				Ni	ine r	nonths ended	September 30, 20	Nine months ended September 30, 2021										
	Infrastructure Li		ife Sciences		Spectrum	Non-operating Corporate	Other and Eliminations	11	NOVATE									
Net (loss) attributable to INNOVATE Corp	12				1				\$	(222.8)								
Less: Discontinued operations										(149.9)								
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	\$	8.3	\$	(13.6)	\$	(9.6)	\$ (58.0)	s —	\$	(72.9)								
Adjustments to reconcile net income (loss) to Adjusted EBITDA:																		
Depreciation and amortization		13.1		0.1		4.3	0.1	-		17.6								
Depreciation and amortization (included in cost of revenue)		8.4				_				8.4								
Other operating expenses		0.1		_		0.9	_			1.0								
Interest expense		6.3		_		7.1	33.2	-		46.6								
Other (income) expense, net		(4.2)		_		2.3	(2.5)	_		(4.4)								
Loss on early extinguishment or restructuring of debt		1.5		_		1.0	10.0	-		12.5								
Income tax expense (benefit)		4.1		_		_	(0.3)	_		3.8								
Noncontrolling interest		0.9		(6.0)		(1.9)	-	(0.9)		(7.9)								
Share-based compensation expense		-		0.1		0.6	1.0	_		1.7								
Nonrecurring Items		0.3		<u> </u>		_	0.5	_		0.8								
COVID-19 Costs		8.3		_		_		_		8.3								
Acquisition and disposition costs		2.5		-		0.6	2.5	0.7		6.3								
Adjusted EBITDA	\$	49.6	\$	(19.4)	\$	5.3	\$ (13.5)	\$ (0.2)	\$	21.8								

© INNOVATE Corp. 2021



(in millions)				Th	ree m	onths ended	September 30, 2	020		
	Infrastructure		L	Life Sciences		Spectrum	Non-operating Corporate	Other and Eliminations	I	NNOVATE
Net (loss) attributable to INNOVATE Corp.	-								\$	(17.3)
Less: Discontinued operations										8.2
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	\$	2.4	\$	(4.3)	s	(14.6)	\$ (8.0)	\$ (1.0)	\$	(25.5)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:										
Depreciation and amortization		2.7		-		1.7	0.1	_		4.5
Depreciation and amortization (included in cost of revenue)		2.3				_	_			2.3
Other operating (income) expense		(0.3)		0.1		9.6				9.4
Interest expense		2.1		-		3.6	12.2			17.9
Other (income) expense, net		(0.1)		0.1		0.3	(7.2)			(6.9)
Income tax expense (benefit)		1.5		-		-	(2.3)	2.2		1.4
Noncontrolling interest		0.1		(1.8)		(1.1)	-	(1.5		(4.3)
Bonus to be settled in equity		-		_			(0.2)			(0.2)
Share-based compensation expense		_		-		0.2	0.7			0.9
Nonrecurring Items		0.4		-		-	0.2	-		0.6
COVID-19 Costs		6.4				_	-			6.4
Acquisition and disposition costs		0.2		<u></u>		0.1	0.8	0.2		1.3
Adjusted EBITDA	s	17.7	\$	(5.9)	s	(0.2)	\$ (3.7)	\$ (0.1	s	7.8

© INNOVATE Corp. 2021

in millions)		Ni	ne months ended	September 30, 20	20	
	Infrastructure	Life Sciences	Spectrum	Non-operating Corporate	Other and Eliminations	INNOVATE
Net (loss) attributable to INNOVATE Corp	-					\$ (87.3)
ess: Discontinued operations						(55.4)
Net Income (loss) attributable to INNOVATE Corp., excluding discontinued operations	\$ 4.0	\$ (8.7)	\$ (23.8)	\$ (72.0)	\$ 68.6	\$ (31.9)
Adjustments to reconcile net income (loss) to Adjusted EBITDA:						
Depreciation and amortization	8.0	0.1	5.1	0.1	-	13.3
Depreciation and amortization (included in cost of revenue)	6.9		<u> </u>	_		6.9
Other operating (income) expenses	(0.2)	0.1	7.4	_		7.3
Interest expense	6.5		10.3	39.4		56.2
Loss on early extinguishment or restructuring of debt	_			9.2		9.2
Other (income) expense, net	-	(2.2)	1.3	(0.8)	(71.3)) (73.0)
Income tax (benefit) expense	2.5	-	-	1.6	(0.4)) 3.7
Noncontrolling interest	0.2	(4.0)	(3.5)	-	0.5	(6.8)
Bonus to be settled in equity	-		—	(0.5)		(0.5)
Share-based compensation expense	-	0.1	0.3	2.2		2.6
Nonrecurring Items	2.2	-	-	5.4		7.6
COVID-19 Costs	15.2				0.00	15.2
Acquisition and disposition costs	0.5	_	0.5	3.1	1.6	5.7
Adjusted EBITDA	\$ 45.8	\$ (14.6)	\$ (2.4)	\$ (12.3)	\$ (1.0)) \$ 15.5

© INNOVATE Corp. 2021